As of the Summer 2020 Release, CIBMTR implemented a hard stop when reporting multiple genetically modified cellular therapies and HCTs that require follow-up forms. This new functionality has been implemented to reduce center reporting burden and redundancies when having to report multiple cellular therapy and HCT events for a single patient.
Instead of having two sets of forms due at different timepoints, all applicable follow-up forms will be due at the same timepoints moving forward (i.e. Forms 2450+4100 or 2100+4100). Duplicate questions on the paired forms will be disabled in identified reporting scenarios, listed in each subpage. Defined hard stops in addition to the custom enabling and disabling will streamline follow-up reporting when a patient receives infusions for multiple indications with overlapping time periods.